Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Anish Thomas(National Cancer Institute), Yves Pommier(National Cancer Institute), Udayan Guha(Beltsville Agricultural Research Center), Susan E. Bates(The Nature Conservancy), Christophe E. Redon(Center for Cancer Research), Éva Szabó(National Cancer Institute), Jiuping Ji(Pancreatic Cancer Action Network), Akira Yuno(National Institutes of Health), Christine Alewine(Dartmouth Psychiatric Research Center), Emerson Padiernos(Center for Cancer Research), Raffit Hassan(National Cancer Institute), Jane B. Trepel(National Institutes of Health), James H. Doroshow(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Mirit I. Aladjem(National Institutes of Health), Min-Jung Lee(Center for Cancer Research), Arun Rajan(National Cancer Institute), Robert J. Kinders(National Cancer Institute), Sunmin Lee(National Institutes of Health), Yiping Zhang(China National Center for Biotechnology Development), Haobin Chen(Washington University in St. Louis), William H. Yutzy(Pancreatic Cancer Action Network), Lan Tran(Pancreatic Cancer Action Network), Linda Sciuto(National Cancer Institute)
Cited by 177
Related Papers
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
|Cellular and Molecular Life Sciences|2001|685
Human topoisomerases and their roles in genome stability and organization
|Nature Reviews Molecular Cell Biology|2022|446